Viva Biotech Holdings (1873) issued an announcement on December 2, 2025, regarding the grant of 8,580,000 share options to employees under its Post-IPO Share Option Scheme. The exercise price was set at HK$2.05 per share, aligning with the listed criteria and quoted market prices on the grant date.

According to the announcement, the share options remain valid until March 30, 2031, with a phased vesting schedule tied to both the Group’s overall performance and individual grantee targets. Key performance benchmarks include revenue growth of 35%, 55%, and 75% in the 2027, 2028, and 2029 financial years, respectively, compared to 2025 levels. All grantees are employees involved in the Group’s contract development and manufacturing operations.

Following this share option issue, the total number of shares remaining available for future grants under the scheme stands at 119,845,000. The Board noted that no additional clawback mechanism was deemed necessary, as existing provisions under the Post-IPO Share Option Scheme already address potential lapses and cancellations.